Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer

In conclusion, MBQ-167 is 10x more potent than other currently available Rac/Cdc42 inhibitors and has the potential to be developed as an anticancer drug, as well as a dual inhibitory probe for the study of Rac and Cdc42. Mol Cancer Ther; 16(5); 805–18. ©2017 AACR.

Source: Molecular Cancer Therapeutics - May 2, 2017 Category: Cancer & Oncology Authors: Humphries-Bickley, T., Castillo-Pichardo, L., Hernandez-OFarrill, E., Borrero-Garcia, L. D., Forestier-Roman, I., Gerena, Y., Blanco, M., Rivera-Robles, M. J., Rodriguez-Medina, J. R., Cubano, L. A., Vlaar, C. P., Dharmawardhane, S. Tags: Small Molecule Therapeutics Source Type: research